Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study(vol 22, 498, 2022)

被引：0
|
作者：
Rayer, Cassandra [1 ]
Nachury, Maria [2 ]
Bourreille, Arnaud [3 ]
Roblin, Xavier [4 ]
Peyrin-Biroulet, Laurent [5 ]
Viennot, Stephanie [6 ]
Flamant, Mathurin [7 ]
Laharie, David [8 ]
Caron, Benedicte [5 ]
Dewitte, Marie [1 ]
Siproudhis, Laurent [9 ]
Fumery, Mathurin [10 ]
Bouguen, Guillaume [9 ,11 ]
机构：
[1] Univ Rennes, CHU Rennes, F-35000 Rennes, France
[2] Univ Lille, CHU Lille, Lille, France
[3] CHU Nantes, Nantes, France
[4] CHU St Etienne, St Etienne, France
[5] Nancy Univ Hosp, Dept Gastroenterol, Inserm U954 Deparment Hepatogastroenterol, Vandoeuvre Les Nancy, France
[6] CHU Caen, Caen, France
[7] Clin Jules Vernes, Nantes, France
[8] Univ Bordeaux, Hop Haut Leveque, Serv Hepatogastroenterol & Oncol Digest, CHU Bordeaux, F-33000 Bordeaux, France
[9] Univ Rennes, Inst NUMECAN Nutrit Metab & Canc, CHU Rennes, INSERM,CIC 1414, F-35000 Rennes, France
[10] Univ Picardie, Serv Hepatogastroenterol & Oncol Digest, CHU Amiens & PeriTox, UMR I0 I, Amiens, France
[11] Serv Malad Appareil Digest, 2 Rue Henri Le Guillou, F-35033 Rennes, France
来源：
BMC GASTROENTEROLOGY | 2023年 / 23卷 / 01期
关键词：
D O I：
10.1186/s12876-022-02636-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] MUCOSAL HEALING WITH A SECOND ANTI-TNF IN PATIENTS WITH ULCERATIVE COLITIS AFTER THE FAILURE OF THE PREVIOUS ANTI-TNF TREATMENT
    Papa, A.
    Pugliese, D.
    De Vitis, I.
    D'Aversa, F.
    Landi, R.
    Felice, C.
    Guidi, L.
    Armuzzi, A.
    Rapaccini, G. L.
    DIGESTIVE AND LIVER DISEASE, 2017, 49 : E203 - E203
  • [42] Ustekinumab demonstrates superior treatment persistence over anti-TNF in Crohn's disease patients previously treated with vedolizumab
    Chiu, H. Y.
    Le, P. H.
    Yeh, P. J.
    Kuo, C. J.
    Lai, M.
    Wu, R. C.
    Chen, C. M.
    Chiu, C. T.
    Chiu, C. H.
    Su, M.
    Pan, Y. B.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1170 - I1172
  • [43] Continuation or Switch to Another Anti-TNFα After Intestinal Resection in Crohn's Disease Patients Previously Exposed to Anti-TNFα?
    Collins, Michael
    Sarter, Helene
    Gower-Rousseau, Corinne
    Nachury, Maria
    Libier, Louise
    Cortot, Antoine
    Zerbib, Philippe
    Colombel, Jean-Frederic
    Desreumaux, Pierre
    Blanc, Pierre
    de Chambrun, Guillaume Pineton
    GASTROENTEROLOGY, 2016, 150 (04) : S810 - S810
  • [44] Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's Disease
    Bressler, Brian
    Yarur, Andres
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Lissoos, Trevor
    Lopez, Claudia
    Natsios, Athanasios
    Saha, Sumit
    Kifnidi, Christina
    Demuth, Dirk
    Patel, Haridarshan
    Mantzaris, Gerassimos J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S373 - S373
  • [45] Effectiveness and safety of vedolizumab in anti-TNF naive patients with inflammatory bowel disease: a multicentre retrospective European Crohn's and Colitis Organisation study
    Kopylov, U.
    Verstockt, B.
    Biedermann, L.
    Sebastian, S.
    Pugliese, D.
    Sonnenberg, E.
    Steinhagen, P. R.
    Arebi, N.
    Ron, Y.
    Kucharzik, T.
    Roblin, X.
    Ungar, B.
    Shitrit, A. Bar-Gil
    Ardizzone, S.
    Molander, P.
    Coletta, M.
    Peyrin-Biroulet, L.
    Bossuyt, P.
    Avni-Biron, I.
    Tsoukal, E. I.
    Allocca, M.
    Katsanos, K.
    Raine, T.
    Sipponen, T.
    Fiorino, G.
    Ben-Horin, S.
    Eliakim, R.
    Armuzzi, A.
    Siegmund, B.
    Baumgart, D. C.
    Kamperidis, N.
    Maharshak, N.
    Maaser, C.
    Mantzaris, G.
    Yanai, H.
    Christodoulou, D.
    Dotan, I.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S29 - S30
  • [46] Available therapeutic options following failure of a first anti-TNF agent
    Alan J Silman
    Nature Reviews Rheumatology, 2009, 5 : 115 - 115
  • [47] Available therapeutic options following failure of a first anti-TNF agent
    Silman, Alan J.
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2009, 5 (03): : 115 - 115
  • [48] Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)
    Garcia, M. J.
    Rivero, M.
    Fernandez-Clotet, A.
    de Francisco, R.
    Sicilia, B.
    Mesonero, F.
    de Castro, M. L.
    Casanova, M. J.
    Bertoletti, F.
    Garcia Alonso, F. J.
    Lopez Garcia, A.
    Julian, B.
    Calvet, X.
    Barreiro-de Acosta, M.
    Jara, L.
    Varela, P.
    Nunez, A.
    Ricart, E.
    Riestra, S.
    Arias, L.
    Rodriguez, M.
    Arranz, L.
    Pajares, R.
    Mena, R.
    Calafat, M.
    Camo, P.
    Jimenez, L.
    Ponferrada, A.
    Madrigal, R. E.
    Llao, J.
    Sese, E.
    Almela, P.
    Codesido, L.
    de la Maza, S.
    Leal, C.
    Sanchez, E.
    Pineda Marino, J. R.
    Domenech, E.
    Chaparro, M.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I121 - I123
  • [49] Sequencing of Anti-TNF Agents and Vedolizumab in the Treatment of Crohn's Disease (CD)
    Huang, Zhongwen
    Ba, Yi
    Wang, Song
    Kamble, Pravin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S433 - S433
  • [50] Accelerated dosing schedule with ustekinumab in anti-TNF refractory Crohn's disease
    Gonzalez, H. Aleman
    Stamp, K.
    Whitehead, E.
    Pattinson, A.
    Turnbull, J.
    Myers, S.
    Talbot, A.
    Sebastian, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I374 - I375
12345